NewGenIvf Group Limited
NIVF · NASDAQ
12/31/2024 | 9/30/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $2 | $0 |
| % Growth | -13.5% | -3.1% | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | $0 | $1 | $0 | $0 |
| % Margin | 28.2% | 43.9% | 13% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $0 | $1 | $0 |
| Operating Income | -$1 | $0 | -$1 | -$0 |
| % Margin | -85.5% | 14.7% | -83.3% | – |
| Other Income/Exp. Net | $1 | $0 | $0 | $1 |
| Pre-Tax Income | -$1 | -$0 | -$1 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$1 | $0 |
| % Margin | -8.5% | -1.3% | -62.9% | – |
| EPS | -23.75 | -6.75 | 165.25 | 117.25 |
| % Growth | -251.9% | -104.1% | 40.9% | – |
| EPS Diluted | -23.75 | -6.75 | 165.25 | 117.25 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 4.6% | 15.4% | 29.7% | – |